<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Venlafaxine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00285</strong>&#160; (APRD00125)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (<span class="caps">SNRI</span>) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00285/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00285/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00285.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00285.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00285.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00285.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00285.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00285">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Venlafaxine Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000186/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000186/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: QYRYFNHXARDNFZ-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 313.180856852</li>
              <li>Average Mass: 313.863</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000186">DBSALT000186</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Effexor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Effexor XR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Elafax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>93413-69-5</td></tr><tr><th>Weight</th><td>Average: 277.4018<br>Monoisotopic: 277.204179113</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>27</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>PNVNVHUZROJLTJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenols and Derivatives</td></tr><tr><th>Direct parent</th><td>Tyrosols and Derivatives</td></tr><tr><th>Alternative parents</th><td>Phenylpropylamines; Anisoles; Alkyl Aryl Ethers; Cyclohexanols; Tertiary Alcohols; Tertiary Amines; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>phenylpropylamine; phenol ether; anisole; cyclohexanol; alkyl aryl ether; tertiary alcohol; cyclic alcohol; tertiary amine; polyamine; ether; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the tyrosols and derivatives. These are compounds containing an hydroxyethyl group atached to the C4 carbon of a phenol group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.</td></tr><tr><th>Pharmacodynamics</th><td>Venlafaxine potentiates the neurotransmitter activity in the central nervous system. Furthermore, venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV) potently inhibit the reuptake of serotonin and norepinephrine and weakly inhibit dopamine reuptake. Both molecules do not bind to muscarinic, histaminergic, or alpha-1 adrenergic receptors. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs.  Both also do not have any monoamine oxidase (MAO) inhibitory activity. </td></tr><tr><th>Mechanism of action</th><td>The exact mechanism of action of venlafaxine is unknown, but appears to be associated with the its potentiation of neurotrasmitter activity in the CNS. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), inhibit the reuptake of both serotonin and norepinephrine with a potency greater for the 5-HT than for the NE reuptake process. Both venlafaxine and the ODV metabolite have weak inhibitory effects on the reuptake of dopamine but, unlike the tricyclics and similar to SSRIs, they are not active at histaminergic, muscarinic, or alpha(1)-adrenergic receptors.</td></tr><tr><th>Absorption</th><td>Venlafaxine is well absorbed. Food does not effect the absorption of venlafaxine or its subsequent metabolism into ODV. Bioavailability is 45% following oral administration.
Time to steady state = 3 days. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>7.5 &#177; 3.7 L/kg [venlafaxine]</li>
	<li>5.7 &#177; 1.8 L/kg [O-desmethylvenlafaxine(active metabolite)]</li>
</ul></td></tr><tr><th>Protein binding</th><td>The degree of binding of venlafaxine to human plasma is 27% &#177; 2% at concentrations ranging from 2.5 to 2215 ng/mL. The degree of ODV binding to human plasma is 30% &#177; 12% at concentrations ranging from 100 to 500 ng/mL. Protein-binding-induced drug interactions with venlafaxine are not expected.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Undergoes extensive first pass metabolism in the liver to its major, active metabolite, ODV, and two minor, less active metabolites, N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. Formation of ODV is catalyzed by cytochrome P450 (CYP) 2D6, whereas N-demethylation is catalyzed by CYP3A4, 2C19 and 2C9. ODV possesses antidepressant activity that is comparable to that of venlfaxine. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Venlafaxine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00054">O-Desmethylvenlafaxine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/54">Details</a></td></tr><tr><td>Venlafaxine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00055">N-Desmethylvenlafaxine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/55">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00054">O-Desmethylvenlafaxine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00437">N,O-Didesmethylvenlafaxine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1134">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00437">N,O-Didesmethylvenlafaxine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00958">N,O-didesmethylvenlafaxine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1137">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00437">N,O-Didesmethylvenlafaxine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01040">N,N,O-Tridesmethylvenlafaxine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1138">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00054">O-Desmethylvenlafaxine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00967">O-Desmethylvenlafaxine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1139">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00055">N-Desmethylvenlafaxine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00437">N,O-Didesmethylvenlafaxine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1140">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Renal elimination of venlafaxine and its metabolites is the primary route of excretion. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). </td></tr><tr><th>Half life</th><td>5 hours</td></tr><tr><th>Clearance</th><td><p>Steady state plasma clearance, venlafaxine = 1.3 &#177; 0.6  L/h/kg;<br>
Steady state plasma clearance, <span class="caps">ODV</span> = 0.4 &#177; 0.2 L/h/kg.</p></td></tr><tr><th>Toxicity</th><td>Most patients overdosing with venlafaxine develop only mild symptoms. However, severe toxicity is reported with the most common symptoms being CNS depression, serotonin toxicity, seizure, or cardiac conduction abnormalities. Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the tricyclic antidepressants than the SSRIs. Doses of 900 mg or more are likely to cause moderate toxicity. Deaths have been reported following large doses.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>CYP2D6*4</td><td>A Allele</td><td>Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5030655" target="_blank">rs5030655 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2D6*6</td><td>T deletion</td><td>Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5030655" target="_blank">rs5030655 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2D6*6</td><td>T deletion, homozygote</td><td>Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>CYP2D6*5</td><td>Deletion</td><td>Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3892097" target="_blank">rs3892097 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2D6*4</td><td>A Allele</td><td>Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2032583" target="_blank">rs2032583 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to antidepressant medication</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17913323" target="_blank" title="Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. [18215618 ]
    Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T: ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404. Epub 2007 Sep 15.">17913323 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2032583" target="_blank">rs2032583 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A &gt; G</td><td>Increase risk of adverse effects</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/22641028" target="_blank" title='# de Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, Bruggeman R, Hoogendijk WJ, Penninx BW: ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013 Aug;13(4):349-53. doi: 10.1038/tpj.2012.16. Epub 2012 May 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22641028'>22641028 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5030655" target="_blank">rs5030655 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2D6*4</td><td>del T allele</td><td>Nausea, vomiting diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3892097" target="_blank">rs3892097 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2D6*6</td><td>A allele</td><td>Nausea, vomiting diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" target="_blank" title="Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.">16958828 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9782</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.852</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6534</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7031</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8031</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5792</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7583</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7407</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7664</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6876</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7287</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7199</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8666</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6762
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9941
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5404 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5486
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6627
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Wyeth pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Osmotica pharmaceutical corp</li>
<li>Actavis totowa llc</li>
<li>Amneal pharmaceuticals</li>
<li>Aurobindo pharma ltd</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Dr reddys laboratories ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva hrvatska doo</li>
<li>Sandoz inc</li>
<li>Vintage pharmaceuticals llc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Wyeth</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li>Direct Pharmaceuticals Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Upstate Pharma LLC</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, extended release</td><td>Oral</td><td>150 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>37.5 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>75 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>100 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>25 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>37.5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>50 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>75 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Venlafaxine HCl 30 225 mg 24 Hour tablet Bottle</td><td>276.98USD</td><td>bottle</td></tr><tr><td>Effexor XR 30 37.5 mg 24 Hour Capsule Bottle</td><td>144.33USD</td><td>bottle</td></tr><tr><td>Venlafaxine HCl 30 37.5 mg 24 Hour tablet Bottle</td><td>114.46USD</td><td>bottle</td></tr><tr><td>Effexor 30 75 mg tablet Bottle</td><td>87.83USD</td><td>bottle</td></tr><tr><td>Effexor 30 25 mg tablet Bottle</td><td>74.82USD</td><td>bottle</td></tr><tr><td>Effexor XR 150 mg 24 Hour Capsule</td><td>5.87USD</td><td>capsule</td></tr><tr><td>Effexor xr 150 mg capsule</td><td>5.65USD</td><td>capsule</td></tr><tr><td>Effexor XR 75 mg 24 Hour Capsule</td><td>5.39USD</td><td>capsule</td></tr><tr><td>Effexor xr 75 mg capsule</td><td>4.76USD</td><td>capsule</td></tr><tr><td>Venlafaxine HCl 150 mg 24 Hour tablet</td><td>4.72USD</td><td>tablet</td></tr><tr><td>Effexor xr 37.5 mg capsule</td><td>4.63USD</td><td>capsule</td></tr><tr><td>Venlafaxine HCl 75 mg 24 Hour tablet</td><td>4.42USD</td><td>tablet</td></tr><tr><td>Effexor 100 mg tablet</td><td>2.92USD</td><td>tablet</td></tr><tr><td>Effexor 75 mg tablet</td><td>2.7USD</td><td>tablet</td></tr><tr><td>Effexor 50 mg tablet</td><td>2.6USD</td><td>tablet</td></tr><tr><td>Effexor 37.5 mg tablet</td><td>2.5USD</td><td>tablet</td></tr><tr><td>Effexor 25 mg tablet</td><td>2.4USD</td><td>tablet</td></tr><tr><td>Venlafaxine hcl 100 mg tablet</td><td>2.36USD</td><td>tablet</td></tr><tr><td>Venlafaxine hcl 75 mg tablet</td><td>2.23USD</td><td>tablet</td></tr><tr><td>Effexor Xr 150 mg Extended-Release Capsule</td><td>2.16USD</td><td>capsule</td></tr><tr><td>Venlafaxine hcl 50 mg tablet</td><td>2.1USD</td><td>tablet</td></tr><tr><td>Effexor Xr 75 mg Extended-Release Capsule</td><td>2.05USD</td><td>capsule</td></tr><tr><td>Venlafaxine hcl 37.5 mg tablet</td><td>2.04USD</td><td>tablet</td></tr><tr><td>Venlafaxine hcl 25 mg tablet</td><td>1.98USD</td><td>tablet</td></tr><tr><td>Apo-Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Co Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Mylan-Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Novo-Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Pms-Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Ratio-Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Sandoz Venlafaxine Xr 150 mg Extended-Release Capsule</td><td>1.2USD</td><td>capsule</td></tr><tr><td>Apo-Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Co Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Mylan-Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Novo-Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Pms-Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Ratio-Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Sandoz Venlafaxine Xr 75 mg Extended-Release Capsule</td><td>1.14USD</td><td>capsule</td></tr><tr><td>Effexor Xr 37.5 mg Extended-Release Capsule</td><td>1.02USD</td><td>capsule</td></tr><tr><td>Apo-Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Co Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Mylan-Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Novo-Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Pms-Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Ratio-Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Sandoz Venlafaxine Xr 37.5 mg Extended-Release Capsule</td><td>0.57USD</td><td>capsule</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6274171</td><td>1997-09-20</td><td>2017-09-20</td></tr><tr><td>United States</td><td>5916923</td><td>1993-06-28</td><td>2013-06-28</td></tr><tr><td>Canada</td><td>2126305</td><td>2006-10-17</td><td>2014-06-20</td></tr><tr><td>Canada</td><td>2199778</td><td>2005-12-20</td><td>2017-03-12</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>215-217 &#176;C (Hydrochloride salt)</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>572 mg/ml (Hydrochloride salt)</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.30e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.69</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.74</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.1</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>14.42</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.91</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>32.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>83.02</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>32.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/2019">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1954">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Thomas P. Jerussi, Chrisantha H. Senanayake, &#8220;Derivatives of (+)-venlafaxine and methods of preparing and using the same.&#8221; U.S. Patent US6197828, issued June, 1994.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6197828&amp;tbm=pts" target="_blank">US6197828 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Golden RN, Nicholas L: Antidepressant efficacy of venlafaxine. Depress Anxiety. 2000;12 Suppl 1:45-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11098413">Pubmed</a></li>
	<li>Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 Oct;26(5):482-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16974189">Pubmed</a></li>
	<li>Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15367045">Pubmed</a></li>
	<li>Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004 Aug;110(3):697-706. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15288411">Pubmed</a></li>
	<li>Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 Feb;45(2):144-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15705120">Pubmed</a></li>
	<li>Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22992668">Pubmed</a></li>
	<li>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19515014">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D08670" target="_blank">D08670 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07187" target="_blank">C07187 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5656" target="_blank">5656 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504593" target="_blank">46504593 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.5454.html" target="_blank">5454 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=9943" target="_blank">9943 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL637" target="_blank">CHEMBL637 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000054" target="_blank">DAP000054 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451866" target="_blank">PA451866 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2237279" target="_blank">2237279 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/venlafax.htm" target="_blank">http://www.rxlist.com/cgi/generic/venlafax.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/venlafaxine.html" target="_blank">http://www.drugs.com/venlafaxine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=eff1794.html&amp;contentName=Effexor%20XR&amp;contentId=277" target="_blank">http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=eff1794.html&amp;contentName=Effexor%20XR&amp;contentId=277 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Venlafaxine" target="_blank">Venlafaxine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N06AX16<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N06#N06">N06 &#8212; PSYCHOANALEPTICS</a></li><li><a href="/atc/N06A#N06A">N06A &#8212; ANTIDEPRESSANTS</a></li><li><a href="/atc/N06AX#N06AX">N06AX &#8212; Other antidepressants</a></li></ul>N06AX23<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N06#N06">N06 &#8212; PSYCHOANALEPTICS</a></li><li><a href="/atc/N06A#N06A">N06A &#8212; ANTIDEPRESSANTS</a></li><li><a href="/atc/N06AX#N06AX">N06AX &#8212; Other antidepressants</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:16.04.92</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00285.pdf?1265922806">show</a>(3.38 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00285.pdf?1265922744">show</a>(36.5 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Amprenavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00248">Cabergoline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cinacalcet is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Clarithromycin is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00907">Cocaine</a></td><td>Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cocaine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Conivaptan is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Darunavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delaviridine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Delavirdine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00449">Dipivefrin</a></td><td>Venlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>Venlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Venlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.</td></tr><tr><td><a href="/drugs/DB01049">Ergoloid mesylate</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00614">Furazolidone</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Imatinib is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Indinavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Lopinavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Lopinavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01233">Metoclopramide</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>Miconazole, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Miconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB04896">Milnacipran</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nelfinavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>Venlafaxine may increase the tachycardic and vasopressor effects of Norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache. </td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01186">Pergolide</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Posaconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Propafenone increases the effect and toxicity of venlafaxine</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>Venlafaxine may increase the tachycardic and vasopressor effects of Pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache. </td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00118">S-Adenosylmethionine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Increased risk of serotonin syndrome. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Terbinafine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Venlafaxine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid St.John's Wort.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>